Erik Sulman, MD, PhD, has been appointed Interim Executive Director of the Duke Cancer Institute (DCI), effective January 5, 2026. Dr. Sulman, an accomplished physician-scientist and nationally recognized leader in radiation oncology, will assume this role while continuing to serve as Chair of the Department of Radiation Oncology at the Duke University School of Medicine. His appointment comes at a notable period of transition for one of the nation’s foremost comprehensive cancer centers.
About Erik Sulman, MD, PhD
Dr. Sulman brings a distinguished record of academic leadership, scientific innovation, and clinical excellence to the interim directorship. Since joining Duke earlier this year, he has already demonstrated a strong commitment to strengthening interdisciplinary programs and advancing the institution’s mission in research and patient care. His career has been defined by impactful contributions to translational cancer research, precision oncology, and molecular radiation biology, with a particular focus on bridging laboratory discovery with clinical application.
Known for his strategic leadership style, Dr. Sulman has guided multidisciplinary teams, supported the development of novel treatment technologies, and mentored numerous trainees who have gone on to become leaders in oncology. His experience navigating complex academic health systems, combined with his dedication to innovation and collaboration, positions him well to guide DCI through this transitional period while continuing to expand the department he leads.
About the Duke Cancer Institute (DCI)
The Duke Cancer Institute is a National Cancer Institute-designated Comprehensive Cancer Center and a central component of the Duke University Health System. DCI integrates world-class research, clinical care, and education to advance the understanding and treatment of cancer on a local, national, and global scale. Its multidisciplinary structure creates a seamless environment in which scientists, clinicians, and educators work together to translate groundbreaking discoveries into improved patient outcomes.
DCI maintains leadership across the continuum of cancer research, including immuno-oncology, genomics, population sciences, global oncology, early-phase clinical trials, and survivorship. It is recognized for delivering patient-centered, highly specialized clinical care and for offering access to innovative clinical trials that provide patients with the most advanced therapeutic options. The institute’s influence extends beyond its campus through national collaborations, international partnerships, and initiatives aimed at strengthening equity and access in cancer care.
Honoring the Leadership of Michael B. Kastan, MD, PhD
Dr. Sulman’s appointment follows the transition of Michael B. Kastan, MD, PhD, who served as the inaugural Executive Director of the Duke Cancer Institute for more than a decade. Dr. Kastan’s visionary leadership was instrumental in shaping DCI’s growth, expanding its scientific programs, and positioning it as a leader in oncologic innovation. His impact has extended well beyond Duke, influencing national and international cancer research communities. His legacy continues to guide the institute’s ongoing commitment to excellence.
Executive Director Search
The search for DCI’s next permanent Executive Director remains in progress. Duke University has expressed appreciation to the search committee for its continued dedication to identifying a leader who can advance the institute’s mission and strategic priorities. During this transitional period, Dr. Sulman’s leadership will ensure stability, continuity, and sustained momentum, allowing DCI to remain focused on scientific discovery, clinical excellence, and improved outcomes for patients with cancer.
Erik Sulman Appointed Dynamic Chair of Radiation Oncology at Duke
Written by Nare Hovhannisyan, MD